Panobinostat for the Treatment of Multiple Myeloma
Laubach JP(1), Moreau P (2), San-Miguel JF (3), Richardson PG (4).
(1) Medical Oncology, Dana Farber Cancer Institute.
(2) University hospital hôtel-dieu, Hematology Department, University Hospital Hôtel-Dieu, Place Alexis Ricordeau, 44093 Nantes cedex 01, France.
(3) Clinical & Translational Medicine, Clínica Universidad de Navarra.
(4) Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute.
Panobinostat is a potent oral deacetylase inhibitor that alters gene expression through epigenetic mechanisms and inhibits protein degradation.
It was recently approved by the US Food and Drug Administration for use in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma who have received ≥ 2 prior regimens, including bortezomib and an immunomodulatory drug.
Panobinostat was approved based on results from the phase 3 PANORAMA 1 trial in patients with relapsed or relapsed and refractory multiple myeloma, which showed that panobinostat plus bortezomib and dexamethasone significantly extended progression-free survival (median, 12.0 months) compared with placebo plus bortezomib and dexamethasone (median, 8.1 months; P < .0001).
Additional ongoing trials are evaluating panobinostat in combination with other partners in the relapsed/refractory and newly diagnosed treatment settings. This review focuses on panobinostat and its mechanism of action, pharmacokinetics, and clinical data in the treatment of relapsed or relapsed and refractory multiple myeloma.
CITATION Clin Cancer Res. 2015 Sep 11. pii: clincanres.0530.2015.